Novel compounds, pharmaceutical compositions containing same, and methods of use for same

A compound of formula:

• wherein:
• R1 is selected from the group consisting of H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH3, —OC(O)CH3 and —OC(O)CF3;
• R2 is —OCH2C(O)NHNH—R5, wherein R5 is selected from the group consisting of
• (a) a phenyl group, optionally substituted with one or more of a halogen or a C1-C8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR6, wherein R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR6, where R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• (d) −C(O)R7, where R7 is selected from the group consisting of a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• R3 and R4 are independently selected from the group consisting of C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
• with the proviso that when R1 is —H, —OCH3, or —OC(O)CF3 and R3 is —(CH2)7CH3, then R2 is not —OCH2C(O)NHNH—R5, where R5 is -p-C6H4Cl, —C(O)CH3, or

A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:

• wherein:
• R1 is selected from the group consisting of H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH3, —OC(O)CH3 and —OC(O)CF3;
• R2 is —OCH2C(O)NHNH—R5, wherein R5 is selected from the group consisting of
• (a) a phenyl group, optionally substituted with one or more of a halogen or a C1-C8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR6, wherein R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR6, where R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• (d) —C(O)R7, where R7 is selected from the group consisting of a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• R3 and R4 are independently selected from the group consisting of C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
• with the proviso that when R1 is —H, —OCH3, or —OC(O)CF3 and R3 is —(CH2)7CH3, then R2 is not —OCH2C(O)NHNH—R5, where R5 is -p-C6H4Cl, —C(O)CH3, or

A method of treating cancer in a subject, comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:

• wherein:
• R1 is selected from the group consisting of H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH3, —OC(O)CH3 and —OC(O)CF3;
• R2 is —OCH2C(O)NHNH—R5, wherein R5 is selected from the group consisting of
• (a) a phenyl group, optionally substituted with one or more of a halogen or a C1-C8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR6, wherein R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR6, where R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• (d) —C(O)R7, where R7 is selected from the group consisting of a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• R3 and R4 and independently selected from the group consisting of C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
• with the proviso that when R1 is —H, —OCH3, or —OC(O)CF3 and R3 is —(CH2)7CH3, then R2 is not —OCH2C(O)NHNH—R5, where R5 is -p-C6H4Cl, —C(O)CH3, or

A method of inhibiting fatty acid synthase activity in a subject comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:

• wherein:
• R1 is selected from the group consisting of H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH3, —OC(O)CH3 and —OC(O)CF3;
• R2 is —OCH2C(O)NHNH—R5, wherein R5 is selected from the group consisting of
• (a) a phenyl group, optionally substituted with one or more of a halogen or a C1-C8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR6, wherein R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR6, where R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• (d) —C(O)R7, where R7 is selected from the group consisting of a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• R3 and R4 and independently selected from the group consisting of C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
• with the proviso that when R1 is —H, —OCH3, or —OC(O)CF3 and R3 is —(CH2)7CH3, then R2 is not —OCH2C(O)NHNH—R5, where R5 is -p-C6H4Cl, —C(O)CH3, or

A method of inhibiting growth of invasive microbial cells in a subject comprising the administration of an effective amount of a pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula I:

• wherein:
• R1 is selected from the group consisting of H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, —OCH3, —OC(O)CH3 and —OC(O)CF3;
• R2 is —OCH2C(O)NHNH—R5, wherein R5 is selected from the group consisting of
• (a) a phenyl group, optionally substituted with one or more of a halogen or a C1-C8 alkyl, which is optionally substituted with one or more of a first substitution group selected from the group consisting of a halogen, —OH, and —OR6, wherein R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (b) a 2-, 3-, or 4-pyridyl, optionally substituted with one or more of a second substitution group selected from the group consisting of a halogen, —OH, and —OR6, where R6 is C1-C8 alkyl, optionally substituted with one or more halogens;
• (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• (d) —C(O)R7, where R7 is selected from the group consisting of a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, alkylaryl, and heterocycle, which is selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole;
• and
• R3 and R4 and independently selected from the group consisting of C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, and alkylaryl;
• with the proviso that when R1 is —H, —OCH3, or —OC(O)CF3 and R3 is —(CH2)7CH3, then R2 is not —OCH2C(O)NHNH—R5, where R5 is -p-C6H4Cl, —C(O)CH3, or